Lightrock India led a $18m Series B1 round in Bugworks Research, a clinical stage multi-indication therapeutics company, with participation from The University of Tokyo Edge Capital, Global Brain, and 3ONE4 Capital. "We are very excited about our lead clinical asset BWC0977 that is potentially the first novel truly broad-spectrum anti-bacterial drug in nearly five decades. We are very honored to welcome a syndicate of world class investors, who join our committed existing-investors in supporting our dual mission of combating AMR and hard to treat cancers," Anand Anandkumar, Bugworks Research CEO.